BRI Logo

Recent Asian Animal Trials Confirm BioResource International, Inc.’s
Xylamax® Enzyme Feed Additive Reduces Feed Costs by Improving Performance

New Vietnam Trial Data to be Presented at Technical Seminar During VIV Asia 2017

Research Triangle Park, N.C. — February 27, 2017— BioResource International, Inc. (BRI), a global biotechnology company specializing in the research, development and manufacture of high-performance enzyme feed additives for optimizing animal nutrition and gut health, announced today that data from new research conducted in Vietnam confirms its Xylamax® enzyme feed additive improves live performance in local broiler breeds. Dr. Duong Duy Dong of Nong Lam University will present the results of the Vietnam trial on March 16th during VIV Asia 2017 in Bangkok, Thailand.

The Vietnam trial evaluated the effect of Xylamax supplementation to standard and low-density corn-soy diets on the digestibility of key nutrients and growth performance of colored-feather chickens. The trial included 600 male and female crossbred chickens raised from one to 84 days. Findings confirmed that Xylamax substantially improved performance in available energy, feed digestibility and conversion rate:

• Xylamax improved the metabolizable energy value of corn-soy diets by at least 146 kcal/kg feed
• Xylamax reduced 84-day adjusted feed conversion rate (FCR) by an average of 10 points, across energy levels
• Xylamax significantly improved digestibility of key nutrients including crude fat, crude fiber and ash

“This Vietnam trial, along with recent trials conducted by leading researchers in India and Thailand, add to the growing body of data confirming Xylamax efficacy in improving poultry performance, using both ‘on-top’ and ‘reformulation’ strategies,” said BRI Technical Manager Dr. James Tyus. “We look forward to working with our partners in the region to help producers mitigate the substantial challenges presented by variability in feed ingredient quality and rising costs.”

Interested parties are welcome to attend Dr. Dong’s technical seminar at VIV Asia (Thursday March 16, Room 215, 10 – 11 a.m.). The BRI team will be available at VIV Asia, Hall 98, Booth PE05 to discuss details regarding Xylamax and other BRI products.

For more information about Xylamax, and results of animal trials conducted to date, please visit

About BRI
Founded in 1999, BRI is a global biotechnology company specializing in the research, development and manufacture of high-performance enzyme feed additives that help poultry and swine producers optimize animal nutrition and gut health. BRI products are effective tools for managing rising feed costs and feed ingredient quality variations in a way that is safe for animals, humans and the environment. The company has earned a reputation as a team of trusted enzyme experts who utilize their scientific expertise to create innovative products that solve nutritional and sustainability challenges facing meat producers around the world. For more information, please visit


Media Contact:
Whitney Smith
Public Relations, BRI

About the author